Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

XtalPi files FDA application for intestinal pain drug candidate

Technology firm XtalPi submitted an Investigational New Drug application to the US Food and Drug Administration to initiate clinical trials for its gut restricted inhibitor KQTD 126

  • XtalPi submits FDA IND application for KQTD-126 intestinal pain drug.
  • KQTD-126 targets TRK family receptors to manage chronic intestinal pain.
  • Preclinical studies show pan-TRK inhibition at sub-nanomolar concentrations.

More from Monday 28 September →